Imugene Ltd. Presents Promising Azer-cel Data at ASCO 2026
Key points
- Azer-cel shows promising clinical activity in CAR T-naive cohort
- Overall response rate of 81% among evaluable patients
- Encouraging responses across various blood cancer types
- Abstract available at asco.org/abstracts
- Oral presentation on 29 May 2026
Full summary
Imugene Limited (ASX:IMU) announced promising results from its azer-cel Phase 1b study, which were published in the American Society of Clinical Oncology (ASCO) abstract. The study, conducted in patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia not previously exposed to autologous CAR T therapy, showed an overall response rate of 81% among the evaluable patients. Responses were observed across multiple lymphoma and leukemia subtypes, including diffuse large B-cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, primary central nervous system lymphoma, follicular lymphoma, and Waldenström macroglobulinemia. Imugene will present updated data during an oral presentation at ASCO on 29 May 2026.
Summary generated by a large language model. Please interpret with care.